(NASDAQ: HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ('NASH') and chronic viral infection, today announced that management will present an update on the Company's business at the H.
The stock is down 45% since the Phase 3 nonalcoholic steatohepatitis Regnerate results for Intercept's obeticholic acid were announced in February, despite the data being positive, Beatty tells investors in a research note.
Non-alcoholic fatty liver disease refers to wide spectrum of liver damage ranging from simple steatosis to steatohepatitis, advanced fibrosis and cirrhosis.
JKB-122, TaiwanJ's effective phase 2 nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) drug candidate, had been licensed out to Newsoara Biopharma Co Ltd, based in Shanghai.
The condition, known as non-alcoholic steatohepatitis, or NASH, is a more advanced form of fatty liver disease, which features inflammation of the liver.
We outline a case of untreated childhood onset growth hormone deficiency (CO-GHD) who presented with type 2 diabetes mellitus (T2DM) and also steatohepatitis. We discuss her management and evidence from the basic sciences and clinical studies which show that her presentation with T2DM and steatohepatitis was likely associated with untreated GHD and that with GH supplementation her condition was ameliorated.
All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.